2021 News

12.07.2021 Press Release IR News

Santen and Aerie to accelerate global deployment of Rhopressa/Rhokiinsa and Rocklatan/Roclanda Expanding the area of exclusive licensing, including Europe and China

12.06.2021 IR News

Corporate Governance Report

11.18.2021 Press Release IR News

Santen and ActualEyes sign a joint development agreement on Phase II clinical trial (Phase II a / PoC study) for a treatment candidate for Fuchs endothelial corneal dystrophy

11.18.2021 Information

Santen and Ube Industries receives Complete Response Letter from FDA for STN1011700/DE-117

11.12.2021 IR News

Santen to Present Latest Data on Omidenepag Isopropyl at AAO 2021

11.08.2021 IR News

Santen Reports the 2nd Quarter Fiscal 2021 Consolidated Performance

10.13.2021 IR News

Aerie Pharmaceuticals Announces Positive Topline Results for Netarsudil Ophthalmic Solution 0.02% Phase 3 Clinical Trial in Japan

10.08.2021 IR News

Santen to Present Latest Data on STN2000100 (DE-128, MicroShunt) at 39th ESCRS

10.01.2021 Press Release IR News

Notice of Corporate Officer Appointments

09.30.2021 Press Release IR News

Singapore National Eye Centre and Santen Announce a Strategic Partnership to Develop and Deploy Internationally an Innovative Educational Programme for Development of the Eye Care Ecosystem in Asia

09.30.2021 IR News

Notice on the Completion of Disposal of Treasury Shares for the Post-delivery Type Performance-Linked Stock Remuneration System

09.28.2021 IR News

Integrated Report Santen Report 2021 has been published

09.21.2021 Information

'IBSA Blind Football European Championships Division2 2021' kicks off in Romania on September 25

09.03.2021 IR News

Santen to Present Latest Data including STN1012700 (DE-127) at APAO 2021

09.01.2021 Press Release

Notice on the Selection to Apply to New Market Segment "Prime Market" on the Tokyo Stock Exchange

09.01.2021 IR News

Notice on the Disposal of Treasury Shares for the Post-delivery Type Performance-Linked Stock Remuneration System

09.01.2021 IR News

Notice on the Selection to Apply to New Market Segment 'Prime Market' on the Tokyo Stock Exchange

08.31.2021 Press Release IR News

Santen and Airdoc Partner to Improve Diagnostic Rate of Fundus Ocular Diseases with AI device in China

08.30.2021 Press Release IR News

Santen Files for Manufacturing and Marketing Approval of STN1008903 (diquafosol sodium) - Improved formulation to reduce the frequency of administration to ease patients' burden -

08.10.2021 Press Release IR News

Santen and Sydnexis execute an exclusive licensing agreement for SYD-101, a novel investigational treatment for progressive childhood myopia

08.06.2021 IR News

Santen Reports the 1st Quarter Fiscal 2021 Consolidated Performance

08.02.2021 Information

Sustainability page on our website has been updated

07.29.2021 IR News

Santen to Present Latest Data including STN1012700 (DE-127) and STN1007603 (DE-076C) at 33rd APACRS 2021 meeting

07.26.2021 Press Release IR News

Santen and IAPB taking action to implement the first ever UN General Assembly resolution recognizing the link between eye health and sustainable development

07.21.2021 IR News

Santen to Present Latest Data on STN2000100 at 2021 ASCRS Annual Meeting

07.21.2021 IR News

Notice on the Completion of Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program

07.08.2021 Press Release IR News

Santen's CO2 emission reduction targets endorsed by the Science Based Targets (SBT) initiative

06.28.2021 IR News

Notice on the Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program

06.24.2021 Press Release IR News

Santen Receives U.S. FDA Approval for Verkazia (Cyclosporine Ophthalmic Emulsion, 0.1%) for the Treatment of Vernal Keratoconjunctivitis in Children and Adults

06.24.2021 IR News

Santen to Present Latest Data on STN2000100 at COS 2021 and 9th WGC

06.03.2021 IR News

Santen to Present Latest Data on Omidenepag Isopropyl at APGC 2021

05.19.2021 Press Release IR News

Santen Announces Medium-Term Plan "MTP2025"

05.19.2021 Press Release IR News

Santen and Glaukos Enter into a New Collaboration in the Development and Commercialization of STN2000100 (DE-128) in the Americas, Australia, and New Zealand

05.18.2021 Press Release IR News

Santen Establishes "Santen Vision for the Earth 2050" Setting Environmental Targets for 2030, Including CO2 Emissions Reduction Targets

05.17.2021 Press Release IR News

Santen expresses a stance to strengthen its gender diversity. -Joining the "30% Club Japan," taking action to increase gender diversity at board and senior management -Becoming a signatory of the "UN Women's Empowerment Principles" promoting gender equality and women's empowerment in the workplace, marketplace and community

05.11.2021 Press Release

Notice of Postponement of "Transition to a Holding Company Structure through Sole-share Transfer and Change in Fiscal Year"

05.11.2021 Press Release IR News

Notice of Board of Director and Corporate Auditor Nominations

05.11.2021 Press Release

Santen Reports Fiscal 2020 Consolidated Performance

05.11.2021 IR News

Santen Reports Fiscal 2020 Consolidated Performance

05.11.2021 IR News

Notice of Postponement of Transition to a Holding Company Structure through Sole-share Transfer and Change in Fiscal Year

04.22.2021 Press Release IR News

Santen has commenced the construction of the new factory in Suzhou to address expanding product demand in China -Toward reinforcing global production and supply structure-

04.09.2021 Press Release

Notice of Recording of Impairment Loss and Revision of Full-Year Earnings Forecasts

04.09.2021 IR News

Notice of Recording of Impairment Loss and Revision of Full-Year Earnings Forecasts

04.06.2021 Information

Santen Presents at a Global Cell Therapy Conference - The Cell & Gene Meeting on the Mediterranean

03.22.2021 Press Release IR News

Notice of Corporate Officer Appointments

03.12.2021 Press Release IR News

Santen Announces Sponsorship of IBSA Blind Football World Grand Prix for the Second Consecutive Year

03.12.2021 Information

Santen Recognized as One of Outstanding Enterprises in 2021 Certified Health and Productivity Management Outstanding Organization (Large Enterprise Category)

02.05.2021 Information

Santen and IAPB Partner to Advocate for Better Eye Health

02.04.2021 Press Release

Santen Reports the 3rd Quarter Fiscal 2020 Consolidated Performance

02.04.2021 Press Release

Notice of Commencement of Preparation for Transition to a Holding Company Structure through Sole-Share Transfer and Change in Fiscal Year

02.04.2021 IR News

(Timely Disclosure) Notice of Commencement of Preparation for Transition to a Holding Company and Change in Fiscal Year

02.04.2021 IR News

Santen Reports the 3rd Quarter Fiscal 2020 Consolidated Performance

02.02.2021 Press Release IR News

Santen and Ube Announces U.S. FDA Acceptance of New Drug Application for STN10117 (DE-117) (JAN: Omidenepag Isopropyl) as a Treatment for Patients with Glaucoma and Ocular Hypertension

02.01.2021 Press Release IR News

Santen and Ube Announces Launch of Glaucoma and Ocular Hypertension Treatment EYBELIS Ophthalmic Solution 0.002% in South Korea

01.08.2021 IR News

Santen to Hold a Presentation for the 39th Annual J.P. Morgan Healthcare Conference

01.08.2021 Information

Corporate Social Responsibility (CSR) page on our website has been updated

01.07.2021 Press Release IR News

Santen Joins the Valuable 500 International Initiative Promoting the Active Participation of People with Disabilities